Skip to main content

ABBOTT LABORATORIES

corporate_fare Company Profile

ABBOTT LABORATORIES

ABT·NYSE·Healthcare·CIK 0000001800

Abbott Laboratories is an Illinois corporation, incorporated in 1900, whose principal business involves the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation, which is expected to enable Abbott to enter the cancer diagnostics market. This acquisition is subject to customary closing conditions, including shareholder approval and regulatory clearances. Abbott operates through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment includes a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. These products are generally sold directly to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers from Abbott-owned distribution centers or public warehouses. Some products are co-marketed, co-promoted, or licensed from other companies. Key products in this segment's therapeutic portfolios include: - Gastroenterology products: Creon™ for pancreatic exocrine insufficiency; Duspatal™ and Dicetel™ for irritable bowel syndrome or biliary spasm; Heptral™, Transmetil™, and Samyr™ for intrahepatic cholestasis or depressive symptoms; and Duphalac™ for colon rhythm regulation. - Women's health products: Duphaston™ for gynecological disorders; and Femoston™ for postmenopausal hormone replacement therapy. - Cardiovascular and metabolic products: Lipanthyl™ and TriCor™ for dyslipidemia and diabetic retinopathy; Omacor™ for hypertriglyceridemia; Physiotens™ for hypertension; and Synthroid™ for hypothyroidism. - Pain and central nervous system products: Serc™ for Ménière's disease and vestibular vertigo; Brufen™ for pain, fever, and inflammation; and Sevedol™ for severe migraines. - Respiratory drugs and vaccines: including the anti-infective clarithromycin.

ABBOTT LABORATORIES (NYSE:ABT) is a publicly traded company in the Healthcare sector. Wiseek monitors ABT SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Abbott Laboratories Reaches Preliminary Settlement in Infant Formula Shareholder Derivative Lawsuits
  • Abbott Cuts Full-Year Outlook, Citing Mild Flu Season and Acquisition Impact
  • Abbott Reports In-Line Q1 Results, Updates FY26 Guidance Post-Exact Sciences Acquisition
  • Abbott Reports Q1 2026 Results, Updates Guidance Reflecting Exact Sciences Acquisition
  • Abbott Completes $21 Billion Exact Sciences Acquisition, Bolstering Cancer Diagnostics

monitoring Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$44.33B
Net Income
$6.52B
Diluted EPS
$3.72
Op. Cash Flow
$9.57B
Free Cash Flow
$7.39B
Gross Profit
$25.01B
Operating Income
$8.05B
Cash & Equivalents
$8.52B
Total Debt
$12.93B
Debt / Equity
0.25×
Net Margin
14.7%
Shares Outstanding
1.74B sh
Source: 10-K · filed 2026-02-20 · accession 0001628280-26-010185

supervised_user_circle Insider Transactions

$4.23M bought $1.44M sold
Net $2.79M buying · 13 transactions by 9 insiders · last 12 months
  • 2026-04-27 STARKS DANIEL J Director
    Open-market purchase 10K sh $926.54K @ $92.65
  • 2026-04-23 Boudreau Philip P EVP AND CFO Officer
    Open-market purchase 2.2K sh $201.3K @ $91.50
  • 2026-04-24 McKinstry Nancy Director
    Grant/Award 2.29K sh
  • 2026-04-24 McKinstry Nancy Director
    Grant/Award 2.31K sh derivative
  • 2026-04-24 Conroy Kevin T Director
    Grant/Award 2.29K sh
  • 2026-04-24 Stratton John G Director
    Grant/Award 2.29K sh
  • 2026-04-24 O'Grady Michael Director
    Grant/Award 2.29K sh
  • 2026-04-24 O'Grady Michael Director
    Grant/Award 5.93K sh derivative
  • 2026-04-24 Blount Sally E. Director
    Grant/Award 2.29K sh
  • 2026-04-24 Roman Michael F Director
    Grant/Award 2.29K sh
  • 2026-04-24 Kumbier Michelle Director
    Grant/Award 2.29K sh
  • 2026-04-24 Babineaux-Fontenot Claire Director
    Grant/Award 2.29K sh
  • 2026-04-24 McDew Darren W Director
    Grant/Award 2.29K sh
  • 2026-04-24 Gonzalez Patricia Paola Director
    Grant/Award 2.29K sh
  • 2026-04-24 Ahuja Nita Director
    Grant/Award 2.29K sh
  • 2026-04-24 STARKS DANIEL J Director
    Grant/Award 2.29K sh
  • 2026-04-24 STARKS DANIEL J Director
    Grant/Award 7.11K sh derivative
  • 2026-03-31 Stratton John G Director
    Grant/Award 382 sh $39.22K @ $102.67 derivative
From SEC Form 4 + 5 (insider beneficial-ownership filings) · last 12 months · view all on SEC EDGAR ↑
$88.38
52-week range $93.92 – $139.06
Market cap
$153.94B
Volume
7.8M (0.6× avg)
3-mo avg 13.4M
Price snapshot as of 2026-05-20 21:44 UTC (Market snapshot (POST))

show_chartPrice Chart

Loading chart...

feed ABT - Latest Insights

ABT
Apr 17, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
ABT
Apr 16, 2026, 10:58 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ABT
Apr 16, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
ABT
Apr 16, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
ABT
Mar 23, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
9
ABT
Mar 23, 2026, 8:54 AM EDT
Filing Type: 8-K
Importance Score:
9
ABT
Mar 13, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ABT
Mar 09, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
8
ABT
Mar 04, 2026, 6:00 AM EST
Source: Reuters
Importance Score:
7
ABT
Feb 25, 2026, 7:01 AM EST
Filing Type: 424B5
Importance Score:
9
ABT
Feb 23, 2026, 6:18 PM EST
Filing Type: FWP
Importance Score:
9
ABT
Feb 20, 2026, 4:05 PM EST
Filing Type: 10-K
Importance Score:
9
ABT
Jan 22, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7